2026 Q2 -tulosraportti
14 päivää sitten
‧48 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 751 | - | - | ||
| 1 | - | - | ||
| 548 | - | - | ||
| 455 | - | - | ||
| 1 345 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 25.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 26.8. | ||
2026 Q1 -tulosraportti 27.5. | ||
2025 Q4 -tulosraportti 25.2. | ||
2025 Q3 -tulosraportti 24.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·26 min sittenNice close to the day, 5% up :)
·3 t sitten
·7 t sittenI see that many here on the forum are concerned about the stock price development. For me, this stock is a lottery ticket I bought because I believe that the Company will succeed and that the ticket will yield a huge profit. Had I wanted to trade, I would have chosen other stocks with better liquidity and greater volatility. For me, therefore, short-term fluctuations in the price mean nothing.- ·7 t sittenCan someone tell this that it's going the wrong way now. What's happening? Is fear of an interest rate hike the reason?
I don't think this is primarily about fear of interest rate hikes. Nykode went quite quickly from around 3.50 kr to 5 kr. Much helped by Moderna/Merck and the renewed interest in cancer vaccines. Then came the emission at 4.40 kr and 65 million new shares. Around 20 % more shares than before. It naturally takes some time for the market to absorb. At the same time, the news flow has calmed down. We haven't received any new Nykode-specific message equivalent to the Moderna/Merck effect. So I actually think we are seeing a quite normal combination of profit-taking, more shares in the market, and less news-driven momentum. The interesting thing is that the company fundamentally has not become weaker since the price was near 5 kr. On the contrary, they have received 286 mill fresh kroner more on the books and significantly reduced financing risk. My guess is therefore that the next proper repricing requires a new Nykode-specific catalyst. Such as a partner agreement, the tax case, clinical data, or other clear progress. - ·1 päivä sittenI think it is petty of Nykode to issue 65 million new shares, and since this affects the market price. I don't remember exactly what the market price was before the issue, but it was probably around 4.5 kr/share. And with this issue, small shareholders get an offer to buy the share for 4.1 kr. Now the issue causes the price to go below 4.1 kroner. What advantage is there in buying the share at 4.1 kr, when the market price is around 4 kr. This is a completely legal practice, but it's the same as giving the finger to small shareholders who were already invested in the share before the issue, especially for those who have held the share for a long time, and eagerly awaited an upturn. Now, a biotechnology stock is a risky stock with a lot of uncertainty. The way they have chosen to carry out the issue makes the share more risky. Now the issue is necessary to raise money, but we small shareholders should have gotten the share for even cheaper money, at the price before the upturn.
A couple of clarifications on the math here: For those of us who owned shares before, it's actually good that the issue happened at a high price. 4.40 was among the year's highest levels; the price was at 2.50-3 as recently as this spring. The higher the price they raise at, the fewer new shares are needed for the same amount, and the less the dilution for us. To demand that small shareholders should have been able to subscribe at the price before the rise is, in practice, asking for greater self-dilution. And the money doesn't disappear even if the price falls. The 286 million is in the company regardless. So when the price is at approx 4 today, you are buying the company, including the fresh money, cheaper than the issue participants paid a week ago. Those who subscribed at 4.40 are in the red. You get the same company with the same full cash box at a lower price than what the best-informed actors voluntarily paid. That's not being fooled; it's coming out better than those who got to participate. What the money bought is also worth noting. The company is now financed past the Abili-T-interim data in 2027, and into 2029 with the tax money. The alternative was to risk a forced issue at a bottom price later, and that is the type of issue that truly crushes small shareholders. Raising at yearly high levels before you have to is the least painful variant found in biotech. One last thing: until now, every rise in NYKD has had a built-in brake; everyone knew an issue was coming sooner or later, and this time it came right after the peak. That brake is gone now. The next positive news, whether it's the tax decision, a partnership agreement, or Abili-T data, has no pending issue hanging over it. Then the price can actually go. Price drops right after issues are completely normal overhang and usually calm down within a few weeks. The values in the company are higher today than two weeks ago, now with the cash to prove it.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 -tulosraportti
14 päivää sitten
‧48 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·26 min sittenNice close to the day, 5% up :)
- ·3 t sitten
- ·7 t sittenI see that many here on the forum are concerned about the stock price development. For me, this stock is a lottery ticket I bought because I believe that the Company will succeed and that the ticket will yield a huge profit. Had I wanted to trade, I would have chosen other stocks with better liquidity and greater volatility. For me, therefore, short-term fluctuations in the price mean nothing.
- ·7 t sittenCan someone tell this that it's going the wrong way now. What's happening? Is fear of an interest rate hike the reason?I don't think this is primarily about fear of interest rate hikes. Nykode went quite quickly from around 3.50 kr to 5 kr. Much helped by Moderna/Merck and the renewed interest in cancer vaccines. Then came the emission at 4.40 kr and 65 million new shares. Around 20 % more shares than before. It naturally takes some time for the market to absorb. At the same time, the news flow has calmed down. We haven't received any new Nykode-specific message equivalent to the Moderna/Merck effect. So I actually think we are seeing a quite normal combination of profit-taking, more shares in the market, and less news-driven momentum. The interesting thing is that the company fundamentally has not become weaker since the price was near 5 kr. On the contrary, they have received 286 mill fresh kroner more on the books and significantly reduced financing risk. My guess is therefore that the next proper repricing requires a new Nykode-specific catalyst. Such as a partner agreement, the tax case, clinical data, or other clear progress.
- ·1 päivä sittenI think it is petty of Nykode to issue 65 million new shares, and since this affects the market price. I don't remember exactly what the market price was before the issue, but it was probably around 4.5 kr/share. And with this issue, small shareholders get an offer to buy the share for 4.1 kr. Now the issue causes the price to go below 4.1 kroner. What advantage is there in buying the share at 4.1 kr, when the market price is around 4 kr. This is a completely legal practice, but it's the same as giving the finger to small shareholders who were already invested in the share before the issue, especially for those who have held the share for a long time, and eagerly awaited an upturn. Now, a biotechnology stock is a risky stock with a lot of uncertainty. The way they have chosen to carry out the issue makes the share more risky. Now the issue is necessary to raise money, but we small shareholders should have gotten the share for even cheaper money, at the price before the upturn.A couple of clarifications on the math here: For those of us who owned shares before, it's actually good that the issue happened at a high price. 4.40 was among the year's highest levels; the price was at 2.50-3 as recently as this spring. The higher the price they raise at, the fewer new shares are needed for the same amount, and the less the dilution for us. To demand that small shareholders should have been able to subscribe at the price before the rise is, in practice, asking for greater self-dilution. And the money doesn't disappear even if the price falls. The 286 million is in the company regardless. So when the price is at approx 4 today, you are buying the company, including the fresh money, cheaper than the issue participants paid a week ago. Those who subscribed at 4.40 are in the red. You get the same company with the same full cash box at a lower price than what the best-informed actors voluntarily paid. That's not being fooled; it's coming out better than those who got to participate. What the money bought is also worth noting. The company is now financed past the Abili-T-interim data in 2027, and into 2029 with the tax money. The alternative was to risk a forced issue at a bottom price later, and that is the type of issue that truly crushes small shareholders. Raising at yearly high levels before you have to is the least painful variant found in biotech. One last thing: until now, every rise in NYKD has had a built-in brake; everyone knew an issue was coming sooner or later, and this time it came right after the peak. That brake is gone now. The next positive news, whether it's the tax decision, a partnership agreement, or Abili-T data, has no pending issue hanging over it. Then the price can actually go. Price drops right after issues are completely normal overhang and usually calm down within a few weeks. The values in the company are higher today than two weeks ago, now with the cash to prove it.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 751 | - | - | ||
| 1 | - | - | ||
| 548 | - | - | ||
| 455 | - | - | ||
| 1 345 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 25.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 26.8. | ||
2026 Q1 -tulosraportti 27.5. | ||
2025 Q4 -tulosraportti 25.2. | ||
2025 Q3 -tulosraportti 24.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 |
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 -tulosraportti
14 päivää sitten
‧48 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 25.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 26.8. | ||
2026 Q1 -tulosraportti 27.5. | ||
2025 Q4 -tulosraportti 25.2. | ||
2025 Q3 -tulosraportti 24.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·26 min sittenNice close to the day, 5% up :)
- ·3 t sitten
- ·7 t sittenI see that many here on the forum are concerned about the stock price development. For me, this stock is a lottery ticket I bought because I believe that the Company will succeed and that the ticket will yield a huge profit. Had I wanted to trade, I would have chosen other stocks with better liquidity and greater volatility. For me, therefore, short-term fluctuations in the price mean nothing.
- ·7 t sittenCan someone tell this that it's going the wrong way now. What's happening? Is fear of an interest rate hike the reason?I don't think this is primarily about fear of interest rate hikes. Nykode went quite quickly from around 3.50 kr to 5 kr. Much helped by Moderna/Merck and the renewed interest in cancer vaccines. Then came the emission at 4.40 kr and 65 million new shares. Around 20 % more shares than before. It naturally takes some time for the market to absorb. At the same time, the news flow has calmed down. We haven't received any new Nykode-specific message equivalent to the Moderna/Merck effect. So I actually think we are seeing a quite normal combination of profit-taking, more shares in the market, and less news-driven momentum. The interesting thing is that the company fundamentally has not become weaker since the price was near 5 kr. On the contrary, they have received 286 mill fresh kroner more on the books and significantly reduced financing risk. My guess is therefore that the next proper repricing requires a new Nykode-specific catalyst. Such as a partner agreement, the tax case, clinical data, or other clear progress.
- ·1 päivä sittenI think it is petty of Nykode to issue 65 million new shares, and since this affects the market price. I don't remember exactly what the market price was before the issue, but it was probably around 4.5 kr/share. And with this issue, small shareholders get an offer to buy the share for 4.1 kr. Now the issue causes the price to go below 4.1 kroner. What advantage is there in buying the share at 4.1 kr, when the market price is around 4 kr. This is a completely legal practice, but it's the same as giving the finger to small shareholders who were already invested in the share before the issue, especially for those who have held the share for a long time, and eagerly awaited an upturn. Now, a biotechnology stock is a risky stock with a lot of uncertainty. The way they have chosen to carry out the issue makes the share more risky. Now the issue is necessary to raise money, but we small shareholders should have gotten the share for even cheaper money, at the price before the upturn.A couple of clarifications on the math here: For those of us who owned shares before, it's actually good that the issue happened at a high price. 4.40 was among the year's highest levels; the price was at 2.50-3 as recently as this spring. The higher the price they raise at, the fewer new shares are needed for the same amount, and the less the dilution for us. To demand that small shareholders should have been able to subscribe at the price before the rise is, in practice, asking for greater self-dilution. And the money doesn't disappear even if the price falls. The 286 million is in the company regardless. So when the price is at approx 4 today, you are buying the company, including the fresh money, cheaper than the issue participants paid a week ago. Those who subscribed at 4.40 are in the red. You get the same company with the same full cash box at a lower price than what the best-informed actors voluntarily paid. That's not being fooled; it's coming out better than those who got to participate. What the money bought is also worth noting. The company is now financed past the Abili-T-interim data in 2027, and into 2029 with the tax money. The alternative was to risk a forced issue at a bottom price later, and that is the type of issue that truly crushes small shareholders. Raising at yearly high levels before you have to is the least painful variant found in biotech. One last thing: until now, every rise in NYKD has had a built-in brake; everyone knew an issue was coming sooner or later, and this time it came right after the peak. That brake is gone now. The next positive news, whether it's the tax decision, a partnership agreement, or Abili-T data, has no pending issue hanging over it. Then the price can actually go. Price drops right after issues are completely normal overhang and usually calm down within a few weeks. The values in the company are higher today than two weeks ago, now with the cash to prove it.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 751 | - | - | ||
| 1 | - | - | ||
| 548 | - | - | ||
| 455 | - | - | ||
| 1 345 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt